← brief for 2026-08-28 · Slowing decline

HFpEF-ABA Score and Finerenone in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: Insights From the FINEARTS-HF Trial.

Article A Peer reviewed Meta-analysis or large trial

Key takeaways

The FINEARTS-HF trial tested finerenone in 702 people with heart failure and mild kidney problems over about two years. The drug lowered the risk of serious kidney or heart events by 23% overall, and helped more in those with higher HFpEF-ABA scores (age, body mass index, and history of atrial fibrillation). This large randomized trial proves finerenone protects kidneys in this group.

Who did this work

Ono R · Docherty KF · Henderson AD · Claggett BL · Desai AS · Lam CSP · Senni M · Shah SJ · Schou M · Voors AA · Amarante F · Lay-Flurrie J

Source

Article · PubMed, the drug frontier · 2026 Aug 27
https://pubmed.ncbi.nlm.nih.gov/42663335/